LAGUNA HILLS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, CA, a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Company management will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on February 5, 2026 DATE: February 5thTIME: 1:30 PM ET REGISTER HERE Available for 1x1 meetings: February 12 and 13. Schedule 1x1 Meeti ...

Core Insights - Nuwellis, Inc. has appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, to enhance its financial leadership in the medical technology sector focused on precision cardiorenal care [1][4]. Company Overview - Nuwellis, Inc. is a medical technology company that develops precision fluid management technologies aimed at improving patient care across the cardiorenal continuum, addressing both acute and chronic conditions [4]. - The company's product portfolio includes both commercially available and development-stage technologies that focus on safety, precision, and scalability for various patient populations [4]. Leadership Experience - Carisa Schultz has extensive experience in healthcare finance, having served as Vice President of Finance at NeueHealth, where she led enterprise finance, treasury, and corporate development [2]. - Schultz's background includes roles at Boston Scientific and various leadership positions in public and private healthcare organizations, along with experience in Big Four public accounting [3]. Product Highlight - The Aquadex SmartFlow® System is designed to remove excess fluid from patients suffering from hypervolemia, with indications for both temporary and extended use in adult and pediatric patients [5].

Core Insights - ResMed reported strong revenue growth of 11% in the December quarter, with a GAAP EPS increase of 16% on revenue of $1.42 billion, driven by device and mask sales growth across various regions [2][3][6] Revenue Growth - In Canada and Latin America, constant-currency device sales increased by 8% and masks and other sales rose by 16%, attributed to resupply growth and new patient setups, along with revenue from the VirtuOx acquisition [1] - Excluding the Residential Care Software (RCS) business, sales in the U.S., Canada, and Latin America rose by 11% (6% on a constant currency basis) [2] - Globally, device sales increased by 7% and masks and other sales grew by 14% on a constant currency basis [2] Margin Expansion - The company achieved a gross margin improvement of 110 basis points year-over-year, with an operating margin increase to 36.3% [6][11] - Management expects fiscal 2026 gross margin to be between 62% and 63%, influenced by currency movements [8] Capital Returns - ResMed declared a quarterly dividend of $0.60 per share and repurchased approximately $175 million worth of shares, increasing planned buybacks to over $600 million for fiscal 2026 [5][19][20] Product Development and Innovation - The company is advancing new products, including the FDA-cleared AI recommender Comfort Match and the F30i fabric mask line, with positive feedback from early users [5][12][13] - Management highlighted the importance of GLP-1 medications as a demand tailwind, noting that patients on both GLP-1 and CPAP are 10-11% more likely to start therapy [6][15][16] Operating Expenses - Operating expenses rose, with SG&A increasing by 15% on a headline basis, driven by employee-related expenses and marketing investments [9] - R&D expenses increased by 12% on a headline basis, with expectations to maintain R&D at 6% to 7% of revenue for fiscal 2026 [10] Cash Flow and Financial Position - Cash flow from operations was reported at $340 million, with capital expenditures of $29 million, leaving the company with $1.4 billion in cash and $753 million in net cash [18]

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against CVRx Inc. ("CVRx†or the "Company†) (NASDAQ:CVRX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 7, 2025, CVRx announced weaker than expected preliminary first quarter results. In the Company's earning. ...

Group 1 - The core viewpoint is that Stryker, a medical equipment maker, has raised its full-year profit forecast due to strong sales of its implants and other medical devices [1] Group 2 - The company is experiencing robust demand for its products, which is contributing to the positive outlook for the year [1] - The increase in profit forecast indicates confidence in the company's growth trajectory within the medical device industry [1]

Financial Data and Key Metrics Changes - ResMed reported an 11% headline revenue growth for Q2 FY2026, with a 9% increase on a constant currency basis, achieving GAAP EPS growth of 16% [7][8][55] - Gross margin increased by 110 basis points year-over-year to 62.3%, driven by component cost improvements and manufacturing efficiencies [58] - Operating profits rose by 19%, with operating margin improving to 36.3% compared to 34% in the prior year [63] Business Line Data and Key Metrics Changes - Global devices revenue grew by high single digits, while masks, accessories, and other revenue saw double-digit growth [9][55] - Residential care software revenue increased by 5% on a constant currency basis, supported by strong performance from the Medifox Dan software vertical [57] Market Data and Key Metrics Changes - In the U.S., Canada, and Latin America, sales increased by 11%, with a 6% increase on a constant currency basis [55] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [56] Company Strategy and Development Direction - ResMed aims to expand its digital health ecosystem, focusing on sleep health and breathing health, while maintaining a strong balance sheet and free cash flow for investments and shareholder returns [14][39] - The company is investing in R&D for next-generation products and enhancing its manufacturing capabilities, including a new distribution center in Indiana [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable high single-digit growth in the residential care software business by FY2027 [11] - The management highlighted the positive impact of GLP-1 medications on patient engagement and adherence to CPAP therapy, indicating a potential tailwind for future growth [78][104] Other Important Information - ResMed returned $263 million to shareholders through dividends and share repurchases during the quarter, with plans to increase share repurchases to over $600 million for FY2026 [67][68] - The company is actively monitoring the global trade environment and regulatory landscape, with no inclusion of CPAP products in CMS's competitive bidding program [37] Q&A Session Summary Question: Strong US mask number - Management noted that the strong growth in masks includes contributions from the Virtuox acquisition, but even without it, there was still double-digit growth in masks and accessories [70][72] Question: Update on GLP-1 landscape - Management confirmed that patients on GLP-1 therapy show a higher motivation to start and adhere to CPAP therapy, with a 10%-11% higher start rate observed [78][80] Question: SG&A growth ahead of revenue growth - Management indicated that the SG&A growth was influenced by the Virtuox acquisition and marketing programs, but underlying growth was tracking closely with revenue [87] Question: Impact of GLP-1 on patient funnel - Management highlighted that GLP-1 medications are bringing more motivated patients into the healthcare system, leading to higher adherence rates for CPAP therapy [80][104] Question: Philips' potential return to the U.S. market - Management stated uncertainty regarding Philips' re-entry into the U.S. market but noted that ResMed is performing well in competing against them in other regions [114][116]

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea. ...

Core Viewpoint - Nuwellis, Inc. has announced a securities purchase agreement for a private placement of shares and warrants, aiming to raise approximately $5 million to support its operations in precision cardiorenal care [1][3]. Group 1: Private Placement Details - The company will sell 994,537 shares of common stock at an effective offering price of $3.09 per share, along with warrants to purchase 1,989,074 additional shares [1]. - The warrants will have an exercise price of $2.84 per share, exercisable immediately upon issuance, and will expire five years after a resale registration statement becomes effective [1]. Group 2: Warrant Inducement Agreement - Nuwellis has entered into a warrant inducement agreement with an investor to immediately exercise certain existing warrants at a reduced exercise price of $3.09, allowing the purchase of 623,585 shares [2]. - In exchange for the immediate exercise, the company will issue new unregistered warrants for an additional 1,247,170 shares at the same exercise price of $2.84, also expiring five years after the effective registration statement [2]. Group 3: Financial Proceeds and Closing - The gross proceeds from both the private placement and the warrant inducement are expected to be around $5 million before deducting fees and expenses, with the closing anticipated on or about January 30, 2026 [3]. - Ladenburg Thalmann & Co. Inc. is acting as the sole placement agent for these transactions [3]. Group 4: Company Overview - Nuwellis, Inc. is focused on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring and therapy [6]. - The company is headquartered in Minneapolis, Minnesota, and aims to support clinical decision-making across various care settings [6][7]. Group 5: Product Information - The Aquadex SmartFlow system is a key product that provides therapy for patients with hypervolemia, indicated for both temporary and extended use in specific patient populations [9].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].